Walker M, Doiron R C, French S D, Feldman-Stewart D, Siemens D R, Mackillop W J, Booth C M
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada.
Department of Urology, Queen's University, Kingston, Ontario, Canada.
Clin Oncol (R Coll Radiol). 2017 Dec;29(12):818-826. doi: 10.1016/j.clon.2017.09.001. Epub 2017 Sep 23.
Bladder-sparing radiotherapy for muscle-invasive bladder cancer (MIBC) may be underutilised in North America. To understand factors driving practice we used the Theoretical Domains Framework (TDF) to identify barriers and enablers of bladder-sparing radiotherapy utilisation.
A convenience sample of Canadian urologists, medical oncologists and radiation oncologists participated in individual semi-structured 1 h interviews. An interview guide was developed using the TDF to assess barriers and enablers of bladder-sparing radiotherapy use. Interviews were recorded and transcribed. Two investigators independently identified barriers and enablers and assigned them to specific themes. Participant recruitment continued until saturation.
In total, 71 physicians were invited to participate and 34 (48%) agreed to be interviewed; 13 urologists, 11 radiation oncologists and 10 medical oncologists. We identified the following barriers to the use of bladder-sparing radiotherapy (relevant TDF domains in parentheses): (1) beliefs that radiotherapy has inferior survival compared with cystectomy (beliefs about consequences); (2) lack of referral from urology to radiation oncology (behavioural regulation; memory, attention and decision-making); (3) lack of 'champions' who advocate for radiotherapy (social and professional role); and (4) inadequate multidisciplinary collaboration (environmental context and resources). Predominant enablers to the use of bladder-sparing radiotherapy included: (1) 'champions' who believe in the value of radiotherapy (social and professional role); (2) beliefs by urologists that radiation oncologists should present radiotherapy options to all patients (social and professional role); (3) institutional policy that all MIBC patients should be seen by multiple specialists (environmental context and resources); (4) system facilitators of radiation oncology referral (i.e. nurse navigator) (environmental context and resources); and (5) patient-driven consultations seeking alternatives to cystectomy (social influences).
These findings identify important barriers and enablers to the use of bladder-sparing radiotherapy in MIBC. Physician beliefs, access to multidisciplinary care and institutional context should be considered in efforts to increase the use of bladder-sparing radiotherapy.
在北美,用于治疗肌肉浸润性膀胱癌(MIBC)的保膀胱放疗可能未得到充分利用。为了解影响实际应用的因素,我们运用理论领域框架(TDF)来确定保膀胱放疗应用的障碍和促进因素。
选取加拿大泌尿外科医生、医学肿瘤学家和放射肿瘤学家组成的便利样本,参与时长1小时的个人半结构化访谈。使用TDF制定访谈指南,以评估保膀胱放疗应用的障碍和促进因素。访谈进行录音和转录。两名研究人员独立确定障碍和促进因素,并将其归入特定主题。持续招募参与者直至饱和。
总共邀请了71名医生参与,34名(48%)同意接受访谈;其中13名泌尿外科医生、11名放射肿瘤学家和10名医学肿瘤学家。我们确定了以下保膀胱放疗应用的障碍(括号内为相关TDF领域):(1)认为与膀胱切除术相比,放疗的生存率较低(对后果的信念);(2)泌尿外科缺乏向放射肿瘤学的转诊(行为调节;记忆、注意力和决策);(3)缺乏倡导放疗的“倡导者”(社会和专业角色);(4)多学科协作不足(环境背景和资源)。保膀胱放疗应用的主要促进因素包括:(1)相信放疗价值的“倡导者”(社会和专业角色);(2)泌尿外科医生认为放射肿瘤学家应向所有患者介绍放疗方案(社会和专业角色);(3)机构政策规定所有MIBC患者应由多名专科医生会诊(环境背景和资源);(4)放射肿瘤学转诊的系统促进因素(即护士导航员)(环境背景和资源);(5)患者驱动的寻求膀胱切除术替代方案的咨询(社会影响)。
这些发现确定了MIBC保膀胱放疗应用的重要障碍和促进因素。在努力增加保膀胱放疗的使用时,应考虑医生的信念、获得多学科护理的机会和机构背景。